Release
📈 Stocks
Zhimeng Biopharma Completes Patient Enrollment for Phase 2/3 ALS Drug Trial
(10 days ago)
Zhimeng Biopharma advances its ALS treatment candidate CB03-154, completing patient enrollment for a pivotal Phase 2/3 clinical trial as it seeks to…